Triiodothyronine (T3) does not induce rankl expression in rat ROS 17/2.8 Cells

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 1, 2008, Pages 109-113

  Saraiva, Patrícia P ^a,b   Teixeira, Silvania S ^a   Nogueira, Célia Regina ^a   Padovani, Carlos Roberto ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b NONE   (Brazil)

Author keywords

Bone; RANKL; Rat; ROS17 2.8 cell; Thyroid hormone

Indexed keywords

EID: 41149119567     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000100015     Document Type: Article

References (18)

1. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science. 289:1508-14.
2. Klaushofer K, Peterlik M. Pathophysiology of fracture healing, Radiologe. 1994;34:709-14.
3. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. PNAS. 2000;97:1566-71.
4. Ferrer-Cañabate J, Tovar I, Martines P. Osteoprotegerina y Sistema RANKL/RANK: el futuro del metabolismo óseo. An Med Intern. 2002;19:385-8.
5. Lakatos P. Thyroid hormones: benefical or deleterious for bone? Calcif Tissue Int. 2003;73:205-9.
6. Takayanagi H, Kim S, Marsuo K, Suzuki H, Suzuki T, Sato K, et al, Rankl maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature. 2002;416:744-9.
7. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lúthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;99:309-19.
8. Bassett JHD, Williams GR. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab. 2003;14:256-64.
9. Brito JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology. 1994;134:196-76.
10. Miura M, Tanaka K, Komatsu Y, Suda M, Yasoda A, Sakuma Y, et al. A novel interaction between thyroid hormones and 1,25(OH)2D3 in osteoclast formation. Biochem Biophys Res Commun. 2002;291:987-94.
11. Kanatani M, Sugimoto T, Sowa Y, Kobayashi T, Kanzawa M, Chihara K, Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J Cell Physiol. 2004;201:17-25.
12. Yen PM. Physiological and Molecular Basis of Thyroid Hormone Action. Physiol Rev. 2001;81:1097-142.
13. Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, et al. Receptor activator of NF-κB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex conteining RANK, TAB2, and TRAF6. Mol Cell Biol. 2002;22:992-1000.
14. Owens JM, Marsuo K, Nicholson GC, Wagner EF, Chambers TJ. Fra-1 potentiates osteoclastic differentiation In osteoclast-macrophage precursor cell-lines. J Cell Physiol. 1999;179: 170-8.
15. Azuma Y, Kaji K, Karagiri R, Takeshira S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000;275:4858-64.
16. Tanabe N, Maeno M, Suzuki N, Fujisaki K, Tanaka H, Ogiso B, et al. IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. Life Sci. 2005;77:615-26.
17. Simsek G, Karter Y, Aydin S, Uzum H. Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism: changes as a result so reversal to euthyroidism. Chin J Physiol. 2003;46:181-6.
18. Kim CH, Kim HK, Shong YK, Lee KU, Kim GS. Thyroid hormone stimulates basal and interleukin (IL)-1-induced IL-6 production in human bone marrow stromal cells: a possible mediator of thyroid hormone-induced bone loss. J Endocrinol. 1999;160:97-102.